Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02927301
Recruitment Status : Recruiting
First Posted : October 7, 2016
Last Update Posted : May 14, 2019
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : February 7, 2020
  Estimated Study Completion Date : October 31, 2024